PLK1

(redirected from polo-like kinase 1)

PLK1

A gene on chromosome 16p12.2 that encodes a member of the CDC5/Polo subfamily of serine/threonine protein kinases, which performs several key functions during the M phase of the cell cycle—e.g., regulating centrosome maturation and spindle assembly, removing cohesins from chromosome arms, inactivating anaphase-promoting complex/cyclosome (APC/C) inhibitors, and regulating mitotic exit and cytokinesis.
 
Molecular pathology
Defects in PLK1 are associated with gastric, thyroid and B-cell malignancies, with increased expression linked to a worse prognosis.
Mentioned in ?
References in periodicals archive ?
Acting on the knowledge that the gene polo-like kinase 1 (PLK1) can become overexpressed during ADT and that its overexpression can also stimulate androgen synthesis, Xiaoqui Liu and colleagues tested the effects of administering the PLK1-inhibitor B12536 with low-dose metformin in prostate cancer cells.
Xiaoqi Liu, an assistant professor of Biochemistry, has claimed that an overabundance of the polo-like kinase 1 (Plk1) molecule during cell growth, as well as a shortage of the p53 molecule, could lead to tumour formation.
Progress Continues Across Expanding Oncology Pipeline With Two Compounds now in Phase III Clinical Development and a Potential First-in-Class Polo-Like Kinase 1 Inhibitor Soon to Enter Phase II
MedPredict's panel also reviews recent advances in other mechanistic approaches to treatment, including angiogenesis/VEGF, vascular disrupting agents, anthracyclines, TRAIL / DR4 / DR5, Bcl-2/Bcl-xL, survivin, cyclin dependent kinase, cMET, EGFR (T790M), antifolate, HDAC / epigenetics, Hedgehog, HSP90, IGF-1, MAGE-A3, MEK, microtubule, apoptosis, kinesin/EG5, aurora kinase, Polo-like kinase 1, mTOR, PI3/AKT, KRAS, and topoisomerase.
The report provides a competitor evaluation in the field of synthetic molecules targeting polo-like kinase 1 (Plk-1), cyclin-dependent kinase (CDK) or aurora kinase for treatment of cancer as of September 2011.
By inhibiting the activity of Polo-like kinase 1 (Plk1), which is highly expressed in proliferating cells and most tumours, BI 6727 effectively disrupts the cell division and induces cell death, thereby inhibiting cancer growth.
Uckun, an investigator at The Saban Research Institute and a member of the Developmental Therapeutics Program of the USC Norris Comprehensive Cancer Center, has recently discovered that radiation-resistant cancer cells can be made radiation-sensitive by specifically inactivating a molecular target comprised of three important signaling proteins, namely polo-like kinase 1 (PLK1), spleen tyrosine kinase (SYK) and STAT3 transcription factor.
Rigel's scientists will be presenting three other poster presentations at the AACR meeting highlighting drug discovery efforts focused on significant cancer targets: Janus Tyrosine Kinase 2 (JAK 2), Polo-Like Kinase 1 (PLK 1) and Protein Kinase C-related Kinase 1 (PRK-1).
The present Competitive Intelligence Report about Novel Mitotic Kinase Inhibitors provides a competitor evaluation in the field of synthetic molecules targeting polo-like kinase 1 (Plk-1), cyclin-dependent kinase (CDK) or aurora kinase for treatment of cancer as of June 2009.
18 /PRNewswire/ -- Cyclacel Limited, the UK-based biopharmaceutical company, announced this week that it discovered a series of novel, potent, and highly selective drugs inhibiting human Polo-like kinase 1 (Plk1).
The present Competitive Intelligence Report about Plk-1 Inhibitors provides a competitor evaluation in the field of synthetic molecules targeting the polo-like kinase 1 for treatment of cancer as of May 2009.
Fluidigm Corporation has announced that the TOPAZ system has been used during the determination of the structure of the Polo-like Kinase 1 (Plk1), a protein known to play a significant role in the progression of the cell cycle.